What is the share price of Ajanta Pharma Ltd (AJANTPHARM) today?
The share price of AJANTPHARM as on 5th December 2025 is ₹2620.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Ajanta Pharma Ltd (AJANTPHARM) share?
The past returns of Ajanta Pharma Ltd (AJANTPHARM) share are- Past 1 week: 2.30%
- Past 1 month: 2.14%
- Past 3 months: 1.07%
- Past 6 months: 1.63%
- Past 1 year: -12.09%
- Past 3 years: 109.81%
- Past 5 years: 147.15%
What are the peers or stocks similar to Ajanta Pharma Ltd (AJANTPHARM)?
The peers or stocks similar to Ajanta Pharma Ltd (AJANTPHARM) include:What is the dividend yield % of Ajanta Pharma Ltd (AJANTPHARM) share?
The current dividend yield of Ajanta Pharma Ltd (AJANTPHARM) is 1.07.What is the market cap of Ajanta Pharma Ltd (AJANTPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ajanta Pharma Ltd (AJANTPHARM) is ₹32839.33 Cr as of 5th December 2025.What is the 52 week high and low of Ajanta Pharma Ltd (AJANTPHARM) share?
The 52-week high of Ajanta Pharma Ltd (AJANTPHARM) is ₹3115.90 and the 52-week low is ₹2327.30.What is the PE and PB ratio of Ajanta Pharma Ltd (AJANTPHARM) stock?
The P/E (price-to-earnings) ratio of Ajanta Pharma Ltd (AJANTPHARM) is 35.68. The P/B (price-to-book) ratio is 8.66.Which sector does Ajanta Pharma Ltd (AJANTPHARM) belong to?
Ajanta Pharma Ltd (AJANTPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Ajanta Pharma Ltd (AJANTPHARM) shares?
You can directly buy Ajanta Pharma Ltd (AJANTPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Ajanta Pharma Ltd
AJANTPHARM Share Price
2,620.600.30% (-7.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AJANTPHARM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AJANTPHARM Performance & Key Metrics
AJANTPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 33.73 | 8.66 | 1.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
91%
Analysts have suggested that investors can buy this stock
from 11 analysts
Price Upside
Earnings Growth
Rev. Growth
AJANTPHARM Company Profile
Ajanta Pharma Limited is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
AJANTPHARM Sentiment Analysis
AJANTPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AJANTPHARM Stock Summary · July 2025
Ajanta Pharma demonstrated robust financial performance in Q1 FY 2026, with a 14% revenue increase driven by strong growth in the U.S. Generics segment, despite facing challenges from rising expenses and a foreign exchange loss. The company’s commitment to sustainable growth is evident through increased R&D investments and strategic expansions in emerging markets, particularly in India and Africa, where it outpaced market growth. While operational efficiency remains strong, with an 80% cash conversion ratio, management acknowledges pressures on margins due to rising personnel costs. Looking ahead, Ajanta Pharma is optimistic about achieving mid- to high single-digit growth, supported by new product launches and a focus on enhancing its therapeutic portfolio.
AJANTPHARM Stock Growth Drivers
AJANTPHARM Stock Growth Drivers
6Strong Financial Performance
Ajanta Pharma reported a 14% increase in total revenue for Q1 FY 2026, reaching Rs.
Product Launches and Market Expansion
In Q1 FY 2026, Ajanta Pharma launched 10 new products in the Branded Generic business,
AJANTPHARM Stock Challenges
AJANTPHARM Stock Challenges
6Decline in Africa Antimalarial Business
The Africa Institution's Antimalarial business has seen a decline, contributing only 3% to total revenue
Challenges in Cardiac Division Growth
The cardiac division's growth has been lower than the Indian Pharmaceutical Market (IPM) growth rate,
AJANTPHARM Forecast
AJANTPHARM Forecasts
Price
Revenue
Earnings
AJANTPHARM Share Price Forecast
AJANTPHARM Share Price Forecast
2025
Current
₹2,628.50
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹2,628.50
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
AJANTPHARM Company Revenue Forecast
AJANTPHARM Company Revenue Forecast
2025
Current
₹4.74
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹4.74
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
AJANTPHARM Stock EPS (Earnings Per Share) Forecast
AJANTPHARM Stock EPS (Earnings Per Share) Forecast
2025
Current
₹72.94
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹72.94
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
AJANTPHARM
AJANTPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
AJANTPHARM Income Statement
AJANTPHARM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,007.12 | 2,149.92 | 2,076.45 | 2,680.06 | 2,915.67 | 3,456.67 | 3,841.28 | 4,293.31 | 4,742.60 | 5,107.14 | ||||||||||
Raw Materials | 425.21 | 455.63 | 440.09 | 672.46 | 795.95 | 915.44 | 1,024.64 | 1,105.78 | 1,096.40 | 3,675.76 | ||||||||||
| Power & Fuel Cost | 18.70 | 27.42 | 32.65 | 38.88 | 43.70 | 54.38 | 65.71 | 66.57 | 70.34 | |||||||||||
| Employee Cost | 295.42 | 376.47 | 430.71 | 485.59 | 548.25 | 645.78 | 785.14 | 900.34 | 1,089.69 | |||||||||||
| Selling & Administrative Expenses | 362.94 | 424.71 | 445.52 | 534.89 | 484.01 | 652.72 | 784.97 | 748.50 | 862.71 | |||||||||||
| Operating & Other expenses | 194.11 | 183.14 | 139.97 | 176.64 | 19.22 | 143.37 | 298.93 | 215.58 | 269.46 | |||||||||||
EBITDA | 710.74 | 682.55 | 587.51 | 771.60 | 1,024.54 | 1,044.98 | 881.89 | 1,256.54 | 1,354.00 | 1,431.38 | ||||||||||
| Depreciation/Amortization | 61.21 | 59.59 | 72.08 | 95.72 | 116.09 | 125.30 | 130.80 | 135.40 | 144.11 | 160.01 | ||||||||||
| PBIT | 649.53 | 622.96 | 515.43 | 675.88 | 908.45 | 919.68 | 751.09 | 1,121.14 | 1,209.89 | 1,271.37 | ||||||||||
| Interest & Other Items | 1.36 | 0.41 | 1.16 | 11.91 | 8.27 | 10.20 | 5.84 | 7.21 | 20.73 | 22.63 | ||||||||||
| PBT | 648.17 | 622.55 | 514.27 | 663.97 | 900.18 | 909.48 | 745.25 | 1,113.93 | 1,189.16 | 1,248.74 | ||||||||||
| Taxes & Other Items | 141.34 | 153.91 | 127.30 | 196.27 | 246.31 | 196.80 | 157.27 | 297.76 | 268.77 | 275.07 | ||||||||||
| Net Income | 506.83 | 468.64 | 386.97 | 467.70 | 653.87 | 712.68 | 587.98 | 816.17 | 920.39 | 973.67 | ||||||||||
| EPS | 38.23 | 35.19 | 29.18 | 35.42 | 49.73 | 54.78 | 45.94 | 64.43 | 72.94 | 77.47 | ||||||||||
| DPS | 8.67 | 0.00 | 6.00 | 8.67 | 6.33 | 6.33 | 7.00 | 51.00 | 28.00 | 28.00 | ||||||||||
| Payout ratio | 0.23 | 0.00 | 0.21 | 0.24 | 0.13 | 0.12 | 0.15 | 0.79 | 0.38 | 0.36 |
AJANTPHARM Company Updates
AJANTPHARM Stock Peers
AJANTPHARM Past Performance & Peer Comparison
AJANTPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Ajanta Pharma Ltd | 35.68 | 8.66 | 1.07% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
AJANTPHARM Stock Price Comparison
Compare AJANTPHARM with any stock or ETFCompare AJANTPHARM with any stock or ETF
AJANTPHARM
AJANTPHARM Holdings
AJANTPHARM Shareholdings
AJANTPHARM Promoter Holdings Trend
AJANTPHARM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
AJANTPHARM Institutional Holdings Trend
AJANTPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AJANTPHARM Shareholding Pattern
AJANTPHARM Shareholding Pattern
AJANTPHARM Shareholding History
AJANTPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in AJANTPHARM
Mutual Funds Invested in AJANTPHARM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Ajanta Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7029% | Percentage of the fund’s portfolio invested in the stock 0.87% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/124 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3076% | Percentage of the fund’s portfolio invested in the stock 1.60% | Change in the portfolio weight of the stock over the last 3 months 0.63% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/91 (+6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2971% | Percentage of the fund’s portfolio invested in the stock 0.76% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 62/93 (-5) |
Compare 3-month MF holding change on Screener
smallcases containing AJANTPHARM stock
smallcases containing AJANTPHARM stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Ajanta Pharma Ltd
AJANTPHARM Events
AJANTPHARM Events
AJANTPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AJANTPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.72 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AJANTPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AJANTPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.72 every year
AJANTPHARM Upcoming Dividends
AJANTPHARM Upcoming Dividends
No upcoming dividends are available
AJANTPHARM Past Dividends
AJANTPHARM Past Dividends
Cash Dividend
Ex DateEx DateNov 10, 2025
Interim 1
Interim 1 | Div/Share: ₹28.00
Dividend/Share
₹28.00
Ex DateEx Date
Nov 10, 2025
Cash Dividend
Ex DateEx DateNov 6, 2024
Interim 1
Interim 1 | Div/Share: ₹28.00
Dividend/Share
₹28.00
Ex DateEx Date
Nov 6, 2024
Cash Dividend
Ex DateEx DateFeb 8, 2024
Interim 2
Interim 2 | Div/Share: ₹26.00
Dividend/Share
₹26.00
Ex DateEx Date
Feb 8, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Special
Special | Div/Share: ₹15.00
Dividend/Share
₹15.00
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateAug 4, 2023
Interim 1
Interim 1 | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 4, 2023
AJANTPHARM Stock News & Opinions
AJANTPHARM Stock News & Opinions
Articles & Videos
Spotlight
Ajanta Pharma Ltd soars 0.12%, up for fifth straight session
Ajanta Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 2609.7, up 0.12% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.09% on the day, quoting at 26009.55. The Sensex is at 85089.75, down 0.02%. Ajanta Pharma Ltd has risen around 1.59% in last one month. Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has risen around 2.76% in last one month and is currently quoting at 22907.85, down 0.19% on the day. The volume in the stock stood at 19677 shares today, compared to the daily average of 72529 shares in last one month.The PE of the stock is 34.25 based on TTM earnings ending September 25.Powered by Capital Market - Live
20 hours agoCapital Market - Live
Spotlight
Ajanta Pharma Ltd rises for third straight session
Ajanta Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2596, up 1.3% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.48% on the day, quoting at 26049.4. The Sensex is at 85227.88, down 0.48%. Ajanta Pharma Ltd has gained around 2.23% in last one month. Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has gained around 1.98% in last one month and is currently quoting at 22887.75, down 0.01% on the day. The volume in the stock stood at 61812 shares today, compared to the daily average of 89941 shares in last one month.The PE of the stock is 33.66 based on TTM earnings ending September 25.Powered by Capital Market - Live
2 days agoCapital Market - Live
Corporate
Ajanta Pharma fixes record date for 1st interim dividend
Ajanta Pharma has fixed 10 November 2025 as record date for payment of first interim dividend. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Ajanta Pharma gains after Q2 PAT jumps 20% YoY to Rs 260 cr; declares dividend of Rs 28/ share
Revenue from operations rose 14.08% YoY to Rs 1,353.73 crore for the quarter ended 30 September 2025. Profit before tax (PBT) stood at Rs 340.81 crore in Q2 FY26, up 17.42% from Rs 290.24 crore reported in the same quarter last year. EBITDA stood at Rs 328 crore in Q2 FY26, up 5.46% as against 311 crore posted in same quarter last year. EBITDA margin was at 24% in Q2 FY26 as against 26% in Q2 FY25. During the quarter, the company's revenue from India stood at Rs 432 crore (up 12% YoY), revenue from Asia was at Rs 310 crore (up 5% YoY), revenue from Africa stood at Rs 221 crore (up 4% YoY) revenue from Africa institution was at Rs 32 crore (down 25% YoY) while revenue from US Generic was at Rs 344 crore (up 48% YoY). As per IQVIA MAT September 2025, Ajanta Pharma's India branded generic performance exceeded IPM growth by 32%. The higher growth came from Volumes increase, which exceeded IPM by 115% & new launches, which exceeded IPM by 39%. On a half-year basis, the company's consolidated net profit rose 11.52% to Rs 515.53 crore on a 13.93% increase in revenue to Rs 2,656.38 crore in H1 FY26 compared with H1 FY25. Meanwhile, the company's board of directors declared a first interim dividend of Rs 28 per share for FY26. The record date for the dividend is 10 November 2025 and the dividend will be paid on or after 20 November 2025. Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified branded generics business spread across India, the Rest of Asia, and Africa. The company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Ajanta Pharma recommends interim dividend
Ajanta Pharma announced that the Board of Directors of the Company at its meeting held on 3 November 2025, inter alia, have recommended the interim dividend of Rs 28 per equity Share (i.e. 1400%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Ajanta Pharma consolidated net profit rises 20.19% in the September 2025 quarter
Net profit of Ajanta Pharma rose 20.19% to Rs 260.19 crore in the quarter ended September 2025 as against Rs 216.48 crore during the previous quarter ended September 2024. Sales rose 14.08% to Rs 1353.73 crore in the quarter ended September 2025 as against Rs 1186.64 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1353.731186.64 14 OPM %24.2226.22 - PBDT383.78324.63 18 PBT340.81290.24 17 NP260.19216.48 20 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ajanta Pharma fixes record date for Dividend
Ajanta Pharma has fixed 10th November 2025 as the record date for the purpose of ascertaining shareholder's entitlement to Interim Dividend, if any to be declared.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ajanta Pharma to announce Quarterly Result
Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Ajanta Pharma Ltd slips for fifth straight session
Ajanta Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2409.1, down 0.64% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24664.4. The Sensex is at 80439.96, up 0.09%.Ajanta Pharma Ltd has lost around 1.75% in last one month.Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has eased around 1.41% in last one month and is currently quoting at 21475.3, down 0.01% on the day. The volume in the stock stood at 98709 shares today, compared to the daily average of 95682 shares in last one month.The PE of the stock is 32.33 based on TTM earnings ending June 25.Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Ajanta Pharma Ltd up for third straight session
Ajanta Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2585, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.44% on the day, quoting at 24823.45. The Sensex is at 80947.08, up 0.47%. Ajanta Pharma Ltd has slipped around 1.93% in last one month. Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has slipped around 0.2% in last one month and is currently quoting at 21959.6, down 0.15% on the day. The volume in the stock stood at 35951 shares today, compared to the daily average of 1.18 lakh shares in last one month.The PE of the stock is 34.13 based on TTM earnings ending June 25.Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 12.09%, vs industry avg of 10.03%
Over the last 5 years, market share increased from 1.07% to 1.13%
Over the last 5 years, net income has grown at a yearly rate of 14.5%, vs industry avg of 20.02%